What Is a BLA in Clinical Trials and the FDA Process?

A Biologics License Application, or BLA, is the formal request a company submits to the U.S. Food and Drug Administration seeking permission to market a biological product. If you think of it as the biological equivalent of a New Drug Application (NDA) for conventional pharmaceuticals, you are mostly right, but the differences matter. Biologics are made from living organisms or their components, and that origin shapes everything about how they are manufactured, tested, and regulated. The BLA is the culmination of years of preclinical research and clinical trials, and getting it approved is one of the most complex regulatory undertakings in medicine.

Why Biologics Need Their Own Application

Traditional drugs are typically small molecules synthesized through chemical processes. Aspirin, for example, is always the same molecule no matter who makes it. Biologics are fundamentally different. They include products like monoclonal antibodies, vaccines, blood and blood components, gene therapies, cellular therapies, and recombinant proteins. Because they are derived from living systems, they are larger, more structurally complex, and more sensitive to changes in how they are produced. A slight shift in temperature during manufacturing or a different strain of host cells can change the final product in ways that matter clinically.

This complexity is why the FDA regulates biologics under a separate legal framework. The Public Health Service Act, specifically Section 351, governs the licensure of biological products, whereas most conventional drugs fall under the Federal Food, Drug, and Cosmetic Act. When a company wants to sell a new biologic in the United States, it files a BLA under Section 351(a) of that act. The distinction is not just bureaucratic. It determines which FDA center reviews the application, what manufacturing standards apply, and how follow-on products (biosimilars) can eventually reach the market.

What Goes Into a BLA

A BLA is a massive document, often running to hundreds of thousands of pages. It has to convince the FDA of three things: that the biologic is safe, that it is effective for its intended use, and that the manufacturing process reliably produces a consistent product. Those three pillars drive the structure of the application.

The clinical sections contain the results of all the trials the company has conducted, from early-phase safety studies in small groups of volunteers through large Phase 3 trials designed to demonstrate that the biologic actually works. These trials generate the efficacy and safety data that form the core of the FDA’s benefit-risk assessment. But unlike a small-molecule drug, where the chemistry is relatively straightforward, a biologic’s manufacturing process is almost inseparable from the product itself. The industry saying “the process is the product” captures this reality.

That is why the Chemistry, Manufacturing, and Controls (CMC) section of a BLA receives intense scrutiny. This section describes every detail of how the biologic is made: the cell lines or organisms used, the growth conditions, purification steps, quality control tests, stability data showing the product holds up over its intended shelf life, and the specifications the final product must meet before it can be released. For cell and gene therapies, the CMC section is especially challenging because batch-to-batch variability is inherent to the product, and developing robust potency assays to measure biological activity remains a significant hurdle in the field.

The nonclinical section covers laboratory and animal studies that characterize the biologic’s pharmacology and toxicology. And a BLA includes proposed labeling, the package insert that prescribers and patients will rely on for dosing, warnings, and other critical information.

How the FDA Reviews a BLA

Once a BLA lands at the FDA, the agency first decides whether to accept it for review at all. This initial check, sometimes called a filing review, happens during roughly the first 60 days. The FDA looks at whether the application is complete enough to permit a substantive review. If critical sections are missing or the data are so disorganized that reviewers cannot evaluate them, the agency can issue a Refuse to File letter, sending the application back before review even begins.

An analysis of Refuse to File letters found that about 85% of the reasons cited were for scientific deficiencies, with drug efficacy and safety concerns accounting for roughly 30% and drug quality issues for about 19%. The remaining reasons were organizational problems or legal issues.

If the application passes that initial screening, the FDA assigns it a review timeline. Standard review gives the agency a target of 10 months from the date the application was received. Priority Review, reserved for products that offer a significant improvement over existing treatments, shortens that to 6 months. During this period, teams of physicians, statisticians, pharmacologists, chemists, and other specialists independently evaluate different parts of the BLA.

Research into the FDA’s filing communications has found that the projected dates for key review milestones were generally consistent with internal targets, and that about half of filing communications contained at least one review issue flagged early in the process.

The review also typically includes an inspection of the manufacturing facility. FDA investigators visit the site where the biologic will be produced to verify that conditions match what the company described in the CMC section, and that the facility follows current Good Manufacturing Practice (cGMP) requirements. For biologics, these inspections carry extra weight because the manufacturing process is so tightly linked to product quality.

The Advisory Committee Meeting

For some BLAs, the FDA convenes an advisory committee, a panel of outside experts who publicly discuss the evidence and vote on whether the benefits outweigh the risks. These meetings are not binding on the FDA, but they carry real influence. The agency’s early indications about whether an advisory committee will be needed tend to be reliable. Research found that about 95% of the FDA’s preliminary comments on advisory committee plans correlated with whether a meeting actually took place.

Advisory committees are more common for first-in-class biologics, products with novel mechanisms that have no approved precedent, or for applications where the safety profile raises questions that benefit from broader expert input. The meetings are open to the public, and patient advocates often testify during the open public hearing portion, making them one of the more transparent steps in the entire process.

Expedited Pathways and How They Apply to Biologics

The FDA has four main expedited programs that can speed up the development or review of a biologic: Fast Track designation, Breakthrough Therapy designation, Accelerated Approval, and Priority Review. These are not mutually exclusive. A single product can qualify for more than one, and many approved biologics have used a combination.

Fast Track: Available when a product addresses a serious condition and fills an unmet medical need. It allows for more frequent meetings with the FDA during development and the possibility of rolling submission, where the company sends completed sections of the BLA as they are finished rather than waiting to submit everything at once.
Breakthrough Therapy: Granted when preliminary clinical evidence indicates the product may offer a substantial improvement over existing therapy. It includes all the features of Fast Track plus more intensive FDA guidance on trial design.
Accelerated Approval: Allows approval based on a surrogate endpoint, a lab measurement or physical sign that is reasonably likely to predict clinical benefit but is not itself a direct measure of how patients feel or survive. The company then has to confirm the benefit with post-approval studies.
Priority Review: Shortens the FDA’s review clock from 10 months to 6 months.

The use of these pathways varies considerably by therapeutic area. For products targeting infectious diseases, Priority Review has been granted at especially high rates, with a median annual designation rate of about 92%, compared with roughly 60% for products developed against non-infectious diseases. Fast Track designation similarly skewed toward infectious disease products. Interestingly, Accelerated Approval was used least often for infectious disease products, with a median rate of only about 5% compared with 20% for non-infectious products.

There is a practical wrinkle with Breakthrough Therapy that is worth knowing. Congress created the designation in 2012 to influence how clinical trials are designed, with the idea that intensive FDA input early on would lead to more efficient trials. But a study of 116 pivotal trials supporting Breakthrough-designated drugs approved between 2013 and 2018 found that 83% of those trials were already underway or completed by the time the designation was actually granted. Among the small group of trials that had not yet started when the designation came through, there was no meaningful difference in trial design features compared with those already running.

⁴

That does not mean the designation is useless. It still confers Priority Review and opens communication channels that can help resolve manufacturing or regulatory questions faster. But the data suggest that its impact on trial design has been more limited than originally envisioned, largely because companies apply for it after their pivotal trials are already locked in.

What Happens When a BLA Is Not Approved

If the FDA determines that a BLA does not support approval, it issues a Complete Response Letter (CRL). This letter outlines the deficiencies the company needs to address before the agency will reconsider the application. CRLs are not public documents, though companies often disclose their existence and general contents voluntarily.

The reasons for a CRL can range from clinical questions, like insufficient evidence of efficacy or unresolved safety concerns, to manufacturing problems that the company needs to fix before the product can be reliably produced at commercial scale. For cell and gene therapies in particular, a recurring issue has been the difficulty of developing potency assays that adequately measure the product’s biological activity. The FDA has cited concerns about the suitability of proposed potency assays and incomplete stability data in CRLs for these products, and companies have sometimes struggled to demonstrate a new assay’s suitability even when resubmitting.

⁵

A CRL is not the end of the road. Companies can resubmit their BLA after addressing the deficiencies, and many products that initially receive CRLs eventually gain approval. But the process adds months or years to the timeline, and it can be costly for smaller companies that may not have the resources to run additional studies or overhaul their manufacturing processes.

The Biosimilar Pathway

When a biologic’s market exclusivity eventually expires, other companies can seek approval for biosimilar versions. Biosimilars are not “generic biologics” in the way generic drugs are identical copies of their reference products. Because biologics are made in living systems and are structurally complex, an exact copy is not possible. Instead, a biosimilar must be shown to be highly similar to the reference product with no clinically meaningful differences.

Biosimilars are approved through an abbreviated licensure pathway under Section 351(k) of the Public Health Service Act, created by the Biologics Price Competition and Innovation Act (BPCIA) of 2009.

⁶ This law allows sponsors to leverage the safety and efficacy data that were already established for the reference product, reducing the amount of clinical testing needed. The extent of required clinical studies depends on how similar the biosimilar is to its reference product at the analytical and functional level.

⁷

A biosimilar can also seek an interchangeability designation, which means it can be substituted for the reference product at the pharmacy without the prescriber’s intervention, much like a generic drug. Getting that designation requires additional data, typically including switching studies that show patients can move back and forth between the biosimilar and the reference product without problems. The interchangeability bar is higher, but it opens the door to broader market adoption and potentially greater cost savings for patients.

Post-Approval Obligations

Approval of a BLA is not the finish line for regulatory oversight. The FDA often attaches postmarketing requirements (PMRs) or postmarketing commitments (PMCs) to an approval. PMRs are legally mandated studies or clinical trials the company must conduct after the product reaches the market. PMCs are studies the company has agreed to conduct. Both are meant to fill remaining knowledge gaps that could not be fully resolved before approval.

⁸

These can include studying how the biologic behaves in special populations like children or people with kidney disease, evaluating long-term safety outcomes, or conducting studies on drug interactions. When the results come in, they sometimes lead to updates to the prescribing information, adding new warnings, adjusting dose recommendations, or expanding the range of patients for whom the product is indicated.

For products that received Accelerated Approval based on a surrogate endpoint, the post-approval confirmatory trial is particularly high stakes. If the trial fails to verify the clinical benefit, the FDA can initiate proceedings to withdraw the product from the market. In recent years, the agency has become more aggressive about enforcing this requirement, pulling several products that lingered on the market for years without confirming their benefit.

The Role of Patient Experience Data

One increasingly visible part of the BLA review process is the use of patient experience data. This includes information gathered directly from patients about how a disease affects their daily lives, what matters most to them in a treatment, and how they perceive the benefits and side effects of a therapy. It can come from patient-reported outcome measures collected during clinical trials, from patient testimony at advisory committee meetings, or from other structured input.

A review of FDA approvals in 2018 found that about 71% of approved new molecular entities reported using patient experience data during the review process. Patient-reported outcomes were the most significant source, used in about 60% of approved drug reviews that year.

⁹

For biologics targeting rare diseases or conditions with limited treatment options, patient input can be especially important. When clinical trial endpoints are hard to define because the disease has never had an approved treatment, what patients report about their symptoms and quality of life can help the FDA evaluate whether a product’s benefits are real and meaningful. This is not a rubber stamp. The FDA still requires rigorous measurement tools and prespecified endpoints. But the growing emphasis on patient experience data reflects a recognition that statistical significance in a lab measurement does not always capture what matters most to the people taking the drug.

How Cell and Gene Therapies Fit In

Cell and gene therapies represent the most complex products regulated through the BLA pathway. A gene therapy might use a viral vector to deliver a functional copy of a gene to a patient’s cells. A cellular therapy might involve collecting a patient’s own immune cells, engineering them to attack cancer, and infusing them back. Each of these steps introduces variability and risk that conventional biologics do not have.

The manufacturing challenges are formidable. Many cell therapies are autologous, meaning each batch is made from a single patient’s cells. That makes traditional concepts like lot-to-lot consistency almost meaningless in the conventional sense. The potency assay problem described earlier in the context of CRLs is endemic to this product class. Measuring whether a batch of engineered immune cells will actually kill tumor cells inside a patient is fundamentally harder than measuring the concentration of a monoclonal antibody in a vial.

Despite these challenges, the FDA has approved a growing number of cell and gene therapy products, and the agency has issued extensive guidance documents to help companies navigate the BLA process for these products. The review is still conducted under the same statutory framework as any other biologic, but the practical emphasis shifts heavily toward manufacturing and product characterization. Companies working in this space often engage with the FDA well before their BLA submission through pre-BLA meetings, where they can discuss their manufacturing strategy, potency assay plans, and any unusual features of their product that might require special regulatory consideration.

For anyone tracking a product’s progress through this system, understanding what a BLA represents helps decode the press releases and regulatory announcements that biotech companies issue. When a company says it has “submitted a BLA,” it means the product has cleared clinical trials and the company believes the evidence supports approval. When the FDA “accepts a BLA for filing,” it means the application passed that initial completeness check and substantive review has begun. And when the FDA sets a PDUFA date, that is the target date by which the agency intends to make its decision, named after the Prescription Drug User Fee Act that established the modern system of review timelines funded in part by fees from the companies themselves.